2024 SoLA

Targeting lipid and energy metabolism for cardiovascular diseases

Next generation NAD⁺ therapeutics via new modalities

Development of cardiovascular therapeutics through regulation of endothelial dysfunction

Genetic and mechanistic insights into triglyceride-rich lipoproteins and cardiometabolic disease

Omega-3 fatty acids: from triglyceride reduction to cardiovascular outcomes

APOC3 metabolism and therapeutic approaches

ANGPTL3/4/8 inhibition: translational insights and clinical development

How should we apply the 2025 dyslipidemia guidelines in real-world Korean practice?

Early and intensive lipid-Lowering after acute coronary syndrome: timing, targets, and real-world challenges

Managing residual atherosclerotic risk: beyond LDL-C toward precision lipid therapy

Bempedoic acid: a non-statin option for LDL-C lowering

The evolving landscape of PCSK9 inhibitors: siRNA, oral agents, and mAbs

Lp(a)-lowering therapies: olpasiran and other emerging agents

CETP inhibitors: revisiting an old target with new molecules

Updated risk stratification and treatment pathways in the 2026 Korean guidelines

Optimizing pharmacologic therapy in the 2026 Korean guidelines

Lifestyle interventions in dyslipidemia care: evidence updates and practical recommendations for Korea

Managing dyslipidemia in special population in the 2026 Korean guidelines 

From basic discovery to clinical translation: macrophage-targeted imaging and therapy for high-risk plaque

Intracellular Ca²⁺ dysregulation links lipotoxicity to defective autophagy

In vitro modeling of atherosclerosis using iPSC-derived blood vessel organoids